Compare Enact Holdings Inc (ACT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Inovio Pharmaceuticals Inc — how do they compare? Enact Holdings Inc trades at $49.44 (market cap $6.75B), while Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M). The key difference: Enact Holdings Inc is far larger — about 85.9× Inovio Pharmaceuticals Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACT | INO | |
|---|---|---|
Market Cap | $6.75B | $78.55M |
Sector | Technology | Health |
52-Week High | $49.38 | $2.87 |
52-Week Low | $34.93 | $0.66 |
Enterprise Value | $7.05B | $49.56M |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.38, up 1.81% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong profitability with a net income margin of 54.51% and ROE of 12.87%, supported by recent earnings beats. Analysts have a consensus price target of $49.00, with 37.5% buy ratings. Recent news highlights Q2 2026 earnings beating estimates and dividend announcements.
The outlook is cautiously optimistic given solid fundamentals and positive earnings trends, but risks include potential overvaluation with a P/S of 5.65 and technical overbought conditions. Investor sentiment is mixed with no sell ratings, yet the stock faces execution risks in a competitive insurance market.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
